Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Equities researchers at Leerink Swann boosted their Q2 2017 earnings per share (EPS) estimates for shares of Alnylam Pharmaceuticals in a report issued on Thursday. Leerink Swann analyst P. Matteis now expects that the biopharmaceutical company will post earnings per share of ($1.15) for the quarter, up from their previous forecast of ($1.22). Leerink Swann has a “Market Perform” rating and a $67.00 price objective on the stock. Leerink Swann also issued estimates for Alnylam Pharmaceuticals’ Q3 2017 earnings at ($1.11) EPS, Q4 2017 earnings at ($1.02) EPS, FY2017 earnings at ($4.53) EPS and FY2018 earnings at ($4.96) EPS.

Other equities analysts have also issued reports about the company. Piper Jaffray Companies set a $116.00 target price on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, May 24th. Ladenburg Thalmann Financial Services set a $80.00 target price on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, May 17th. Vetr lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 target price on the stock. in a research note on Monday, May 15th. Chardan Capital decreased their target price on Alnylam Pharmaceuticals from $110.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, May 15th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $102.00 target price on shares of Alnylam Pharmaceuticals in a research note on Thursday, June 22nd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Alnylam Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $79.79.

ILLEGAL ACTIVITY NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/08/07/leerink-swann-comments-on-alnylam-pharmaceuticals-inc-s-q2-2017-earnings-nasdaqalny.html.

Alnylam Pharmaceuticals (NASDAQ ALNY) opened at 82.44 on Monday. Alnylam Pharmaceuticals has a 52-week low of $31.38 and a 52-week high of $86.92. The company’s market cap is $7.11 billion. The firm has a 50-day moving average price of $80.45 and a 200-day moving average price of $59.96.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.22) by $0.03. Alnylam Pharmaceuticals had a negative net margin of 705.11% and a negative return on equity of 42.90%. The business had revenue of $19 million during the quarter, compared to the consensus estimate of $22.91 million. During the same quarter in the prior year, the firm earned ($1.21) EPS. The business’s revenue was up 160.3% on a year-over-year basis.

In related news, EVP Akshay Vaishnaw sold 11,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 23rd. The stock was sold at an average price of $75.00, for a total transaction of $825,000.00. Following the transaction, the executive vice president now directly owns 21,297 shares in the company, valued at approximately $1,597,275. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Michael Mason sold 9,375 shares of the firm’s stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $70.00, for a total value of $656,250.00. Following the transaction, the vice president now owns 5,625 shares in the company, valued at $393,750. The disclosure for this sale can be found here. Insiders have sold a total of 64,125 shares of company stock worth $4,325,000 over the last quarter. Corporate insiders own 4.30% of the company’s stock.

A number of institutional investors have recently bought and sold shares of ALNY. Dimensional Fund Advisors LP raised its position in Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 111,350 shares of the biopharmaceutical company’s stock valued at $4,170,000 after buying an additional 695 shares during the last quarter. AQR Capital Management LLC bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at about $1,036,000. Teachers Advisors LLC raised its position in Alnylam Pharmaceuticals by 10.6% in the fourth quarter. Teachers Advisors LLC now owns 73,576 shares of the biopharmaceutical company’s stock valued at $2,755,000 after buying an additional 7,048 shares during the last quarter. Macquarie Group Ltd. raised its position in Alnylam Pharmaceuticals by 10.0% in the fourth quarter. Macquarie Group Ltd. now owns 17,755 shares of the biopharmaceutical company’s stock valued at $665,000 after buying an additional 1,614 shares during the last quarter. Finally, Peregrine Capital Management LLC raised its position in Alnylam Pharmaceuticals by 7.5% in the first quarter. Peregrine Capital Management LLC now owns 221,909 shares of the biopharmaceutical company’s stock valued at $11,723,000 after buying an additional 15,477 shares during the last quarter. Institutional investors and hedge funds own 88.93% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.